Barinthus Biotherapeutics (BRNS) Asset Utilization Ratio (2021 - 2025)
Barinthus Biotherapeutics' (BRNS) quarterly Asset Utilization Ratio came in at 0.14 in Q4 2025, up 68.31% YoY from 0.09 in Q4 2024, and up 15.14% on a QoQ basis from 0.13 in Q3 2025.
Barinthus Biotherapeutics (BRNS) Asset Utilization Ratio (2021 - 2025) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 5 years of Asset Utilization Ratio data on file, last reported at 0.14 in Q4 2025.
- Quarterly Asset Utilization Ratio rose 68.31% year-over-year to 0.14 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.14 (up 68.31% YoY) and the FY2024 annual result came in at 0.08, up 2313.59% from the prior year.
- Asset Utilization Ratio grew to 0.14 in Q4 2025, from 0.13 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.16 in Q4 2022 to a low of 0.0 in Q4 2021.
- A 5-year average of 0.07 and a median of 0.05 in 2022 frame the typical range for Asset Utilization Ratio.
- Annual changes were most pronounced in 2022 — Asset Utilization Ratio surged 16323.46% — and 2024, when it slumped 98.58%.
- Tracing BRNS's Asset Utilization Ratio over 5 years: stood at 0.0 in 2021, then soared by 16323.46% to 0.16 in 2022, then slumped by 97.8% to 0.0 in 2023, then jumped by 2276.96% to 0.09 in 2024, then jumped by 68.31% to 0.14 in 2025.
- The last three Asset Utilization Ratio figures came in at 0.14 (Q4 2025), 0.13 (Q3 2025), and 0.09 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 0.90 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 0.54 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 0.13 |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 0.13 |
| 10 | Barinthus Biotherapeutics | 25.01 Mn | 25.01 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.14 |
| Sep 30, 2025 | 0.13 |
| Dec 31, 2024 | 0.09 |
| Sep 30, 2024 | 0.08 |
| Mar 31, 2024 | 0.00 |
| Dec 31, 2023 | 0.00 |
| Sep 30, 2023 | 0.03 |
| Jun 30, 2023 | 0.05 |
| Mar 31, 2023 | 0.11 |
| Dec 31, 2022 | 0.16 |
| Sep 30, 2022 | 0.14 |
| Jun 30, 2022 | 0.11 |
| Mar 31, 2022 | 0.05 |
| Dec 31, 2021 | 0.00 |
| Sep 30, 2021 | 0.00 |
| Jun 30, 2021 | 0.02 |
| Mar 31, 2021 | 0.04 |